Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ · Healthcare
$5.01-1.96%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $363.76M
- P/E ratio
- —
- EPS
- —
- Volume
- 1,775,263
- 52-week high
- —
- 52-week low
- —
- Open
- $5.12
- Day high
- $5.58
- Day low
- $4.96
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $0 | -$137.06M | -$1.91 |
| 2024 | $67.43M | -$165.84M | -$2.33 |
| 2023 | $0 | -$292.19M | -$4.47 |
| 2022 | $0 | -$236.81M | -$4.48 |
| 2021 | — | -$158.73M | -$3.72 |
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
- CEO
- Julia Marie Eastland
- Employees
- 106
- Country
- US
- IPO date
- Apr 3, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Zentalis Pharmaceuticals, Inc.'s stock price today?
- ZNTL is trading at $5.01 as of Jul 20, 2026.
- What is Zentalis Pharmaceuticals, Inc.'s market cap?
- Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $363.76M.
- Does Zentalis Pharmaceuticals, Inc. pay a dividend?
- Zentalis Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Zentalis Pharmaceuticals, Inc. in?
- Zentalis Pharmaceuticals, Inc. operates in the Healthcare sector.